Bionical Emas is a global Early Access Programs (EAP) and Clinical Trial Supply (CTS) group bringing life-changing medicines to patients around the world. Our range of services and capabilities benefit many of the world’s leading pharma and biotech companies.
Emas Pharma was originally formed in 1998 to support US pharma companies looking to work across Europe. 11 years later in 2009, Bionical was established as a Clinical Trial Supply business serving the global pharma and biotech industry.
The two organizations subsequently merged in 2016 to broaden service offerings and strengthen it’s global footprint. In 2018, Bionical Emas proudly founded the Early Access Programs division, giving a unique opportunity to help patients around the world gain access to life-changing medicines.
In December 2024, Bionical Emas sold its Clinical Development division to allow the Company to further specialize, with a clear vision to become the number one Early Access Programs (EAP) and Clinical Trial Supply (CTS) provider in the world.
Here at Bionical Emas, our outstanding people are driven by their passion for changing patients’ lives. We work together as one team to build long-term partnerships and consistently deliver excellence, whilst pioneering new approaches and being accountable for their success.
We champion a supportive, inclusive and open environment where everyone feels like they belong. We are proud of our people and what they achieve every day by being bold, creative and flexible. Most importantly, we have a lot of fun along the way!
We embrace a holistic approach to quality in every aspect of the company. Our robust processes and Quality Management System complies with international and national regulations and guidelines to enable our teams to deliver services and products to clients and patients around the world.
